Technical Analysis for MBIO - Mustang Bio, Inc.

Grade Last Price % Change Price Change
D 0.27 -4.61% -0.01
MBIO closed down 4.61 percent on Friday, November 1, 2024, on 40 percent of normal volume. It was able to find support at its 50 day moving average.
Earnings due: Nov 12
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Wide Bands Range Expansion 0.00%
Calm After Storm Range Contraction -4.61%
Wide Bands Range Expansion -4.61%
Gapped Down Weakness -4.61%
Wide Bands Range Expansion -13.42%
Upper Bollinger Band Touch Strength -13.42%
Calm After Storm Range Contraction -9.09%
NR7 Range Contraction -9.09%
Narrow Range Bar Range Contraction -9.09%

   Recent Intraday Alerts

Alert Time
50 DMA Support about 22 hours ago
Down 5% about 22 hours ago
Down 3% about 22 hours ago
Up 3% about 22 hours ago
Fell Below Previous Day's Low about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Mustang Bio, Inc. Description

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology, which uses the patient’s own T cells to engage and destroy specific tumors. The Company, through its agreement with City of Hope National Medical Center, is using three novel CAR T therapies in the development of cancer treatments, including human epidermal growth factor receptor 2 CAR T technology, CS1-specific CAR T technology, and prostate stem cell antigen CAR T technology.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immune System Immunotherapy Cancer Treatment Cancer Immunotherapy Gene Therapy Virotherapy Cancer Cell Epidermal Growth Factor Receptor T Cell Chimeric Antigen Receptor Immunotherapy Products Cancer Immunotherapy Product Cellectis

Is MBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.969
52 Week Low 0.1281
Average Volume 1,745,681
200-Day Moving Average 0.57
50-Day Moving Average 0.26
20-Day Moving Average 0.25
10-Day Moving Average 0.29
Average True Range 0.03
RSI (14) 50.50
ADX 31.63
+DI 31.53
-DI 13.97
Chandelier Exit (Long, 3 ATRs) 0.27
Chandelier Exit (Short, 3 ATRs) 0.31
Upper Bollinger Bands 0.33
Lower Bollinger Band 0.18
Percent B (%b) 0.58
BandWidth 58.58
MACD Line 0.01
MACD Signal Line 0.01
MACD Histogram 0.0045
Fundamentals Value
Market Cap 2.24 Million
Num Shares 8.37 Million
EPS -8.93
Price-to-Earnings (P/E) Ratio -0.03
Price-to-Sales 0.00
Price-to-Book 3.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.31
Resistance 3 (R3) 0.31 0.30 0.30
Resistance 2 (R2) 0.30 0.29 0.30 0.30
Resistance 1 (R1) 0.28 0.28 0.28 0.28 0.30
Pivot Point 0.27 0.27 0.27 0.27 0.27
Support 1 (S1) 0.26 0.26 0.25 0.25 0.24
Support 2 (S2) 0.24 0.25 0.24 0.23
Support 3 (S3) 0.23 0.24 0.23
Support 4 (S4) 0.22